Patients with widely differing degrees of cardiovascular risk can derive benefit from effective lipid-lowering therapy with statins, including patients with normal or low cholesterol levels. Clinical trials with fluvastatin have shown that it is effective in patients across a broad spectrum of cardiovascular risk. The lipid-lowering effects of fluvastatin are smaller than some statins, but major clinical outcome studies have consistently demonstrated morbidity and mortality benefits with reductions of low-density lipoprotein cholesterol of <30%. As treatment with statins is generally life-long and patients often receive multiple concomitant medications, optimal statin therapy should be well tolerated and serious consideration should be given to the avoidance of drug interactions. Although serious side-effects of statins are very rare, it is important that fluvastatin is less susceptible to drug interactions than other statins, because serious side-effects of statin therapy are generally associated with concomitant medications affecting statin metabolism. In addition, an extended-release formulation of fluvastatin has been developed to provide liver selectivity with a sustained exposure to the drug, thus improving its efficacy, and safety and tolerability profiles.
|Titolo:||The use of statins in optimising reduction of cardiovascular risk : focus on fluvastatin|
CORSINI, ALBERTO (Primo)
|Parole Chiave:||3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors ; atherosclerosis ; hypercholesterolemia ; adverse effects ; drug interactions|
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||mag-2004|
|Digital Object Identifier (DOI):||10.1111/j.1368-5031.2004.00154.x|
|Appare nelle tipologie:||01 - Articolo su periodico|